Difference between revisions of "Idarubicin (Idamycin)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
|||
| Line 4: | Line 4: | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 06:31, 13 May 2012
General information
Class/mechanism: Anthracycline analog of Daunorubicin (Cerubidine), binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.[1][2][3][4]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Idarubicin (Idamycin) patient drug information (Chemocare)[5]
- Idarubicin (Idamycin) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Idarubicin (Idamycin) package insert
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) package insert
- ↑ Idarubicin (Idamycin) package insert (locally hosted backup)
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)
- ↑ Idarubicin (Idamycin) patient drug information (Chemocare)
- ↑ Idarubicin (Idamycin) patient drug information (UpToDate)